VIR Vir Biotechnology, Inc. Stock Quote

VIR [NASD]

Index	-	P/E	-	EPS (ttm)	-3.10	Insider Own	5.30%	Shs Outstand	127.74M	Perf Week	-3.36%
Market Cap	4.73B	Forward P/E	-	EPS next Y	-1.08	Insider Trans	-2.83%	Shs Float	112.96M	Perf Month	-24.60%
Income	-390.30M	PEG	-	EPS next Q	-0.48	Inst Own	88.20%	Short Float	7.63%	Perf Quarter	-25.32%
Sales	72.60M	P/S	65.18	EPS this Y	56.50%	Inst Trans	7.21%	Short Ratio	12.02	Perf Half Y	-44.76%
Book/sh	5.10	P/B	6.99	EPS next Y	54.40%	ROA	-42.50%	Target Price	-	Perf Year	-24.25%
Cash/sh	5.52	P/C	6.46	EPS next 5Y	7.00%	ROE	-56.90%	52W Range	25.31 - 141.01	Perf YTD	33.12%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-41.40%	52W High	-74.72%	Beta	-
Dividend %	-	Quick Ratio	2.80	Sales past 5Y	-	Gross Margin	-	52W Low	40.85%	ATR	1.95
Employees	340	Current Ratio	2.80	Sales Q/Q	-64.90%	Oper. Margin	-	RSI (14)	35.77	Volatility	4.22% 5.00%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-85.50%	Profit Margin	-	Rel Volume	0.72	Prev Close	36.39
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 05 AMC	Payout	-	Avg Volume	716.42K	Price	35.65
Recom	2.20	SMA20	-6.19%	SMA50	-16.16%	SMA200	-17.81%	Volume	517,200	Change	-2.03%

Jun-04-21

Resumed

Robert W. Baird

Neutral

$45

Jan-27-21

Downgrade

JP Morgan

Neutral → Underweight

$30

Jan-20-21

Reiterated

H.C. Wainwright

Buy

$100 → $125

Oct-05-20

Initiated

BofA Securities

Buy

$55

Sep-14-20

Upgrade

Goldman

Neutral → Buy

$48 → $54

Sep-11-20

Upgrade

JP Morgan

Underweight → Neutral

$29

Aug-20-20

Initiated

Needham

Buy

$62

Mar-19-20

Downgrade

JP Morgan

Neutral → Underweight

$26

Mar-13-20

Downgrade

Goldman

Buy → Neutral

Feb-27-20

Downgrade

Robert W. Baird

Neutral → Underperform

$17

Feb-04-20

Downgrade

JP Morgan

Overweight → Neutral

$25 → $26

Nov-14-19

Initiated

Robert W. Baird

Neutral

Nov-05-19

Initiated

JP Morgan

Overweight

$25

Nov-05-19

Initiated

Goldman

Buy

$37

Nov-05-19

Initiated

Cowen

Outperform

Nov-05-19

Initiated

Barclays

Overweight

$25

Jul-29-21 03:05PM	Earnings Preview: Vir Biotechnology, Inc. (VIR) Q2 Earnings Expected to Decline Zacks
Jul-28-21 01:08PM	11 Best Pharma and Biotech Stocks to Buy According to Jim Simons Euclidean Capital Insider Monkey
08:51AM	Europe buys 220,000 doses of Vir, GSK's experimental COVID-19 treatment MarketWatch
07:09AM	European Commission To Procure 220K Doses Of Glaxo-Vir Biotech's COVID-19 Antibody Benzinga
06:20AM	GSK and Vir Biotechnology Announce Joint Procurement Agreement with European Commission for COVID-19 Treatment, Sotrovimab GlobeNewswire
Jul-22-21 04:05PM	Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2021 Financial Results on August 5, 2021 GlobeNewswire
Jul-21-21 08:06AM	Calculating The Fair Value Of Vir Biotechnology, Inc. (NASDAQ:VIR) Simply Wall St.
Jul-16-21 10:59AM	Vir Biotech (VIR) Begins Dosing in Phase II Hepatitis B Study Zacks
Jul-15-21 09:46AM	Vir Biotechnology Starts Dosing In Mid-Stage Hepatitis B Trial With Combination Therapy Benzinga
09:41AM	Vir initiates open-label Phase 2 study for experimental hepatitis B treatment MarketWatch
08:30AM	Vir Biotechnology Initiates Phase 2 Clinical Trial Evaluating the Combination of VIR-2218 and VIR-3434 as a Functional Cure Regimen for Chronic Hepatitis B Virus Infection GlobeNewswire
Jun-25-21 07:17PM	Vir's stock gains on early results from clinical trials for its hepatitis B treatment candidate MarketWatch -8.23%
03:02PM	Vir Biotech's HBV Candidates Show Positive Safety Profiles Benzinga
08:50AM	Vir Biotechnology Presents New Clinical Data from Ongoing Trials of VIR-2218 and VIR-3434 in Patients with Chronic Hepatitis B Virus Infection at the International Liver Congress 2021 GlobeNewswire
Jun-21-21 12:53PM	30 states likely to miss President Bidens July 4 vaccination goal, and Brazils death toll has topped 500,000 MarketWatch +6.41%
11:41AM	GSK - Vir Biotech's Sotrovimab Reduces Hospitalization, Risk Of Death In Adult COVID-19 Patients Benzinga
07:29AM	Vir, GSK say new data confirms their COVID-19 treatment can reduce hospitalization and death MarketWatch
07:06AM	GSK and Vir Biotechnology Announce Continuing Progress of the COMET Clinical Development Program for Sotrovimab GlobeNewswire
Jun-14-21 08:00AM	Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Oral and Poster Presentations at EASL 2021 GlobeNewswire
Jun-02-21 04:05PM	Vir Biotechnology to Participate in the Goldman Sachs 42nd Annual Global Healthcare Conference GlobeNewswire +6.90%
May-28-21 05:21PM	Vir Biotechnology CEO on its covid-19 drug candidate winning FDA nod for emergency use Yahoo Finance Video
10:44AM	U.S. stops distributing Lilly's COVID-19 antibody therapy in six states, instead recommends Regeneron's treatment MarketWatch
May-27-21 08:10AM	Vir Biotech Stock Jumps After FDA Emergency Use Approval COVID-19 Antibody Drug Benzinga -5.59%
07:44AM	Vir Biotech (VIR)/Glaxo COVID-19 Drug Gets FDA Emergency Nod Zacks
06:29AM	GlaxoSmithKline and Vir win FDA emergency authorization for COVID antibody treatment in adults and children MarketWatch
May-26-21 06:57PM	GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives Emergency Use Authorization from the US FDA for Treatment of Mild-to-Moderate COVID-19 in High-Risk Adults and Pediatric Patients GlobeNewswire
05:55PM	U.S. FDA gives emergency use approval for GSK-Vir COVID-19 antibody drug Reuters
May-24-21 12:27PM	Glaxo (GSK)/ Vir Biotech's COVID-19 Antibody Gets CHMP Nod Zacks
May-21-21 11:56AM	GlaxoSmithKline - Vir Biotech's Antibody COVID-19 Treatment Wins CHMP's Positive Scientific Opinion Benzinga
09:26AM	CORRECTION -- EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnologys Sotrovimab For the Early Treatment of COVID-19 GlobeNewswire
08:04AM	EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnologys Sotrovimab For the Early Treatment of COVID-19 GlobeNewswire
02:19AM	Need To Know: Analysts Just Made A Substantial Cut To Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates Simply Wall St.
May-19-21 06:44AM	The Zacks Analyst Blog Highlights: GlaxoSmithKline, Sanofi, CureVac and Vir Biotechnology Zacks
May-10-21 04:05PM	Vir Biotechnology Reminds Stockholders of 2021 Annual General Meeting Details GlobeNewswire -9.82%
May-07-21 05:53AM	GSK and Vir Biotechnology Announce the Start of the EMA Rolling Review of VIR-7831 (sotrovimab) for the Early Treatment of COVID-19 GlobeNewswire
May-06-21 07:35PM	Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:05PM	Vir Biotechnology Provides Corporate Update and Reports First Quarter 2021 Financial Results GlobeNewswire
Apr-29-21 05:04PM	Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Apr-22-21 04:01PM	Vir Biotechnology to Provide Corporate Update and Report First Quarter 2021 Financial Results on May 6, 2021 GlobeNewswire
Apr-21-21 08:50AM	Brii Biosciences, Vir Biotech, VBI Vaccines Start Combination Therapy Hepatitis B Study Benzinga
08:00AM	Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B Business Wire
08:00AM	Brii Biosciences, Vir Biotechnology and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B GlobeNewswire
06:52AM	What's in the Cards for Eli Lilly (LLY) This Earnings Season? Zacks
Apr-17-21 06:00AM	Could Vir Biotechnology Be a Millionaire Maker Stock? Motley Fool
Apr-16-21 07:14AM	Glaxo (GSK)/ Vir Biotech COVID-19 Antibody Under Review in EU Zacks
Apr-15-21 09:51AM	GSK and Vir Biotechnology Announce EMA Review of Dual-Action Monoclonal Antibody VIR-7831 for the Early Treatment of COVID-19 GlobeNewswire
08:59AM	UPDATE 2-EMA starts review of GSK's monoclonal antibody to treat COVID-19 patients Reuters
Apr-08-21 08:30AM	Vir Biotechnology Announces New Research Demonstrating Novel Mechanisms by Which SARS-CoV-2 Enters Host Cells GlobeNewswire
Apr-06-21 04:01PM	Vir Biotechnology to Present at the 20th Annual Needham Virtual Healthcare Conference GlobeNewswire
Apr-05-21 09:08AM	Vir Biotech's VIR-7831 Maintains Activity Against California Variant Of COVID-19 Infection Benzinga
08:00AM	Vir Biotechnology Announces New Preclinical Research Demonstrating VIR-7831 Maintains Neutralizing Activity Against the SARS-CoV-2 California Variant GlobeNewswire
Mar-31-21 01:33PM	Biotech Stock Roundup: BLUE/BMY's CAR T Therapy Nod, KLDO's COVID-19 Study News & More Zacks +7.33%
Mar-29-21 08:44AM	Eli Lilly, Vir and Glaxo say Phase 2 trial combining antibodies reduced viral load by 70% at day 7 MarketWatch -6.11%
08:30AM	Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19 PR Newswire
08:30AM	Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19 GlobeNewswire
Mar-26-21 12:42PM	GlaxoSmithKline, Vir Biotechnology Seek Emergency FDA Authorization For COVID-19 Drug Benzinga
08:40AM	GlaxoSmithKline and Vir Biotech seek FDA emergency authorization for COVID antibody treatment MarketWatch
08:30AM	GSK and Vir Biotechnology Announce Submission of Emergency Use Authorization Request to FDA for VIR-7831 for the Early Treatment of COVID-19 GlobeNewswire
Mar-25-21 10:55PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIR ACCESSWIRE +7.84%
Mar-24-21 01:03AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIR PR Newswire -6.77%
Mar-21-21 10:29PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIR Newsfile
Mar-18-21 05:13PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIR PR Newswire -9.73%
Mar-16-21 10:33PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIR ACCESSWIRE
02:09PM	Biotech Stock Roundup: REGN's Cancer Drug Positive, COVID-19 Updates From NVAX & More Zacks
07:35AM	AstraZeneca to supply U.S. with extra 500,000 doses of COVID-19 antibody-based cocktail MarketWatch
Mar-14-21 09:21PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIR Newsfile
06:35AM	Can Vir Biotechnology Distinguish Itself In The Vaccine Market? TipRanks
Mar-12-21 09:33AM	Vir Biotech (VIR)/Glaxo COVID-19 Drug Cuts Hospitalization Risk Zacks -14.57%
08:04AM	Vir Biotechnology, Inc. (VIR) Surges 32.1%: Is This an Indication of Further Gains? Zacks
06:20AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIR PR Newswire
Mar-11-21 05:12PM	Why Vir Biotechnology Stock Soared Today Motley Fool +32.06%
04:18PM	Biotech Stock Catapults After GSK-Partnered Covid Drug Succeeds In Key Test Investor's Business Daily
08:38AM	Virs Covid-19 Antibody Works Well, Sending Shares Flying Barrons.com
08:19AM	The Daily Biotech Pulse: Contrasting COVID-19 Treatment Readouts From Roche, Vir, Delay In Kadmon's FDA Review, Alzheimer's Data From Prothena Benzinga
06:45AM	Vir Biotech Soars as Covid Therapy Found Effective at Cutting Deaths Investing.com
05:13AM	Vir/GSK's COVID-19 Antibody Therapy Cuts Hospitalization, Deaths by 85%, Seeks FDA Emergency Use Nod Benzinga
Mar-10-21 08:22PM	Vir Biotechnology and GSK Announce VIR-7831 Reduces Hospitalization and Risk of Death in Early Treatment of Adults with COVID-19 GlobeNewswire
12:05AM	New Forecasts: Here's What Analysts Think The Future Holds For Vir Biotechnology, Inc. (NASDAQ:VIR) Simply Wall St.
Mar-07-21 08:55PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIR Newsfile
Mar-05-21 09:04AM	Vir Biotechnology and GlaxoSmithKline Expand Their COVID Partnership to Flu Motley Fool +13.89%
07:54AM	NIH stops clinical trials for two experimental antibody COVID-19 treatments MarketWatch
Mar-04-21 02:47PM	Biotech Stock Roundup: REGN, VIR's COVID-19 Updates, KMPH's Drug Approval & More Zacks -5.05%
12:52PM	Why Vir Biotechnology Stock Is Falling Today Motley Fool
10:27AM	U.S. COVID death toll above 518,000 as Biden adds voice to outrage at Texas and Mississippi for reopening MarketWatch
08:35AM	Are Options Traders Betting on a Big Move in Vir Biotechnology (VIR) Stock? Zacks
08:29AM	NIH tells Vir that experimental COVID-19 therapy may not benefit patients MarketWatch
Mar-03-21 04:35PM	Vir Stock Craters On Weak Results For Glaxo-Partnered Covid Treatment Investor's Business Daily -27.64%
02:57PM	Vir Shares Plummeted Today. What to Know. Barrons.com
12:55PM	Why Vir Biotechnology Stock Is Dropping Today Motley Fool
09:00AM	Vir Biotechnology and GSK Provide Update on NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19 GlobeNewswire
Feb-25-21 04:01PM	Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results GlobeNewswire
Feb-17-21 02:20PM	Vir Biotechnology and GlaxoSmithKline Expand Their Partnership Motley Fool +18.77%
01:00PM	Why Vir Biotechnology Stock Is Higher Today Motley Fool
09:29AM	Vir and GSK Will Collaborate on Flu Therapy Barrons.com
08:10AM	Vir, GSK ink new R&D deal MarketWatch
07:10AM	GSK, Vir Biotech to expand COVID-19 research partnership for other diseases Reuters
07:04AM	GSK and Vir Biotechnology Expand Coronavirus Collaboration to Advance New Therapeutics for Influenza and Other Respiratory Viruses GlobeNewswire
Feb-11-21 04:01PM	Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021 GlobeNewswire
Feb-01-21 11:30AM	Reddit-fueled saga a very poor way to stick it to the man, says expert Yahoo Finance Video
10:34AM	Return On Capital Employed Overview: Vir Biotechnology Benzinga

Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Virgin Herbert	EVP, Research & CSO	Jul 27	Option Exercise	1.53	1,375	2,104	101,075	Jul 28 07:34 PM
Virgin Herbert	EVP, Research & CSO	Jul 27	Sale	36.72	1,375	50,490	99,700	Jul 28 07:34 PM
Pang Phillip	Chief Medical Officer	Jul 21	Option Exercise	1.57	4,630	7,292	113,907	Jul 23 05:00 PM
Pang Phillip	Chief Medical Officer	Jul 21	Sale	37.44	4,630	173,347	109,277	Jul 23 05:00 PM
SATO VICKI L	Director	Jul 19	Sale	37.20	15,174	564,509	1,626,962	Jul 20 08:51 PM
MORE ROBERT J	Director	Jul 15	Sale	35.56	11,670	415,012	46,029	Jul 19 08:20 PM
Virgin Herbert	EVP, Research & CSO	Jul 13	Option Exercise	1.53	1,375	2,104	101,075	Jul 14 05:46 PM
Virgin Herbert	EVP, Research & CSO	Jul 13	Sale	36.72	1,375	50,490	99,700	Jul 14 05:46 PM
Pang Phillip	Chief Medical Officer	Jul 07	Option Exercise	5.17	5,000	25,875	114,277	Jul 08 05:32 PM
Pang Phillip	Chief Medical Officer	Jul 07	Sale	40.39	5,000	201,931	109,277	Jul 08 05:32 PM
MORE ROBERT J	Director	Jul 01	Sale	44.92	11,670	524,270	57,699	Jul 06 05:01 PM
Rice Steven J.	Chief Administrative Officer	Jun 25	Option Exercise	12.76	3	38	20,003	Jun 29 05:12 PM
Rice Steven J.	Chief Administrative Officer	Jun 25	Sale	50.00	3	150	20,000	Jun 29 05:12 PM
Virgin Herbert	EVP, Research & CSO	Jun 23	Option Exercise	1.53	8,000	12,240	99,700	Jun 24 04:36 PM
SATO VICKI L	Director	Jun 21	Sale	46.17	15,174	700,515	1,642,136	Jun 22 07:57 PM
MORE ROBERT J	Director	Jun 17	Sale	43.95	11,670	512,840	69,369	Jun 21 05:08 PM
Pang Phillip	Chief Medical Officer	Jun 16	Option Exercise	5.17	5,000	25,875	114,277	Jun 17 05:04 PM
Pang Phillip	Chief Medical Officer	Jun 16	Sale	43.67	5,000	218,346	109,277	Jun 17 05:04 PM
Virgin Herbert	EVP, Research & CSO	Jun 15	Option Exercise	1.53	1,375	2,104	93,075	Jun 17 05:03 PM
Virgin Herbert	EVP, Research & CSO	Jun 15	Sale	45.29	1,375	62,274	91,700	Jun 17 05:03 PM
MORE ROBERT J	Director	Jun 03	Sale	44.56	11,670	520,033	81,039	Jun 07 08:36 PM
Pang Phillip	Chief Medical Officer	Jun 02	Option Exercise	0.85	10,000	8,550	119,277	Jun 03 07:30 PM
Pang Phillip	Chief Medical Officer	Jun 02	Sale	41.49	10,000	414,874	109,277	Jun 03 07:30 PM
Virgin Herbert	EVP, Research & CSO	Jun 01	Option Exercise	1.53	1,375	2,104	93,075	Jun 02 05:38 PM
Virgin Herbert	EVP, Research & CSO	Jun 01	Sale	42.51	1,375	58,451	91,700	Jun 02 05:38 PM
MORE ROBERT J	Director	May 20	Sale	44.50	11,670	519,351	89,335	May 24 09:25 PM
SATO VICKI L	Director	May 19	Sale	43.80	15,174	664,601	1,653,936	May 20 07:53 PM
Virgin Herbert	EVP, Research & CSO	May 18	Option Exercise	1.53	1,375	2,104	93,075	May 19 04:39 PM
Virgin Herbert	EVP, Research & CSO	May 18	Sale	45.03	1,375	61,916	91,700	May 19 04:39 PM
Virgin Herbert	EVP, Research & CSO	May 04	Option Exercise	1.53	1,375	2,104	93,075	May 05 07:36 PM
Virgin Herbert	EVP, Research & CSO	May 04	Sale	46.03	1,375	63,291	91,700	May 05 07:36 PM
Virgin Herbert	EVP, Research & CSO	Apr 27	Option Exercise	1.53	7,900	12,087	99,600	Apr 28 04:41 PM
Virgin Herbert	EVP, Research & CSO	Apr 27	Sale	49.50	7,900	391,077	91,700	Apr 28 04:41 PM
Virgin Herbert	EVP, Research & CSO	Apr 19	Option Exercise	1.53	2,340	3,580	94,040	Apr 20 06:18 PM
Virgin Herbert	EVP, Research & CSO	Apr 19	Sale	48.00	2,340	112,320	91,700	Apr 20 06:18 PM
Virgin Herbert	EVP, Research & CSO	Apr 16	Option Exercise	1.53	3,500	5,355	91,700	Apr 19 08:00 PM
Virgin Herbert	EVP, Research & CSO	Apr 13	Option Exercise	1.53	5,560	8,507	93,760	Apr 15 05:36 PM
Virgin Herbert	EVP, Research & CSO	Apr 13	Sale	43.57	5,560	242,244	88,200	Apr 15 05:36 PM
Virgin Herbert	EVP, Research & CSO	Apr 09	Option Exercise	1.53	14,000	21,420	88,200	Apr 12 08:23 PM
Parrish Jay	Chief Business Officer	Apr 01	Option Exercise	1.52	6,944	10,520	16,204	Apr 05 05:00 PM
Parrish Jay	Chief Business Officer	Apr 01	Sale	51.40	6,944	356,956	9,260	Apr 05 05:00 PM
Virgin Herbert	EVP, Research & CSO	Mar 23	Option Exercise	1.53	7,900	12,087	82,100	Mar 25 05:26 PM
Virgin Herbert	EVP, Research & CSO	Mar 23	Sale	53.60	7,900	423,408	74,200	Mar 25 05:26 PM
Virgin Herbert	EVP, Research & CSO	Mar 10	Option Exercise	1.53	2,340	3,580	76,540	Mar 12 04:28 PM
Virgin Herbert	EVP, Research & CSO	Mar 10	Sale	48.00	2,340	112,320	74,200	Mar 12 04:28 PM
Virgin Herbert	EVP, Research & CSO	Mar 09	Option Exercise	1.53	5,560	8,507	79,760	Mar 10 04:58 PM
Virgin Herbert	EVP, Research & CSO	Mar 09	Sale	44.80	5,560	249,086	74,200	Mar 10 04:58 PM
Parrish Jay	Chief Business Officer	Mar 01	Option Exercise	1.51	6,944	10,520	16,204	Mar 03 04:35 PM
Parrish Jay	Chief Business Officer	Mar 01	Sale	63.44	6,944	440,531	9,260	Mar 03 04:35 PM
Virgin Herbert	EVP, Research & CSO	Feb 23	Option Exercise	1.53	18,900	28,917	82,100	Feb 25 04:25 PM
Virgin Herbert	EVP, Research & CSO	Feb 23	Sale	63.74	7,900	503,577	74,200	Feb 25 04:25 PM
Pang Phillip	Chief Medical Officer	Feb 16	Option Exercise	0.85	10,000	8,550	77,277	Feb 18 05:01 PM
Pang Phillip	Chief Medical Officer	Feb 12	Option Exercise	0.85	10,000	8,550	67,277	Feb 17 05:25 PM
Virgin Herbert	EVP, Research & CSO	Feb 09	Option Exercise	1.53	7,900	12,087	41,100	Feb 10 04:33 PM
Virgin Herbert	EVP, Research & CSO	Feb 09	Sale	71.16	7,900	562,161	33,200	Feb 10 04:33 PM
Parrish Jay	Chief Business Officer	Feb 01	Option Exercise	1.55	6,944	10,729	229,166	Feb 02 06:00 PM
Parrish Jay	Chief Business Officer	Feb 01	Sale	69.91	6,944	485,424	222,222	Feb 02 06:00 PM
Virgin Herbert	EVP, Research & CSO	Jan 26	Option Exercise	1.53	31,300	47,889	64,500	Jan 27 06:39 PM
Virgin Herbert	EVP, Research & CSO	Jan 26	Sale	48.17	31,300	1,507,806	33,200	Jan 27 06:39 PM
Virgin Herbert	EVP, Research & CSO	Jan 15	Option Exercise	1.53	10,530	16,111	43,730	Jan 19 05:00 PM
Virgin Herbert	EVP, Research & CSO	Jan 15	Sale	38.00	10,530	400,140	33,200	Jan 19 05:00 PM
Virgin Herbert	EVP, Research & CSO	Jan 12	Option Exercise	1.53	3,805	5,822	37,005	Jan 13 06:38 PM
Virgin Herbert	EVP, Research & CSO	Jan 12	Sale	29.36	3,805	111,696	33,200	Jan 13 06:38 PM
Parrish Jay	Chief Business Officer	Jan 04	Option Exercise	1.49	6,945	10,313	229,167	Jan 05 04:40 PM
Parrish Jay	Chief Business Officer	Jan 04	Sale	26.32	6,945	182,795	222,222	Jan 05 04:40 PM
Virgin Herbert	EVP, Research & CSO	Dec 24	Option Exercise	1.53	9,500	14,535	33,200	Dec 28 06:39 PM
Virgin Herbert	EVP, Research & CSO	Dec 22	Option Exercise	1.53	3,805	5,822	27,505	Dec 23 06:06 PM
Virgin Herbert	EVP, Research & CSO	Dec 22	Sale	31.19	3,805	118,683	23,700	Dec 23 06:06 PM
Virgin Herbert	EVP, Research & CSO	Dec 08	Option Exercise	1.53	3,805	5,822	27,505	Dec 10 05:00 PM
Virgin Herbert	EVP, Research & CSO	Dec 08	Sale	31.27	3,805	118,966	23,700	Dec 10 05:00 PM
Parrish Jay	Chief Business Officer	Dec 01	Option Exercise	1.51	6,945	10,522	229,167	Dec 02 05:48 PM
Parrish Jay	Chief Business Officer	Dec 01	Sale	31.53	6,945	218,968	222,222	Dec 02 05:48 PM
Virgin Herbert	EVP, Research & CSO	Nov 27	Option Exercise	1.53	2,930	4,483	26,630	Dec 01 07:02 PM
Pang Phillip	Chief Medical Officer	Nov 27	Option Exercise	0.85	7,500	6,412	57,277	Dec 01 07:03 PM
Virgin Herbert	EVP, Research & CSO	Nov 27	Sale	30.00	2,930	87,900	23,700	Dec 01 07:02 PM
Virgin Herbert	EVP, Research & CSO	Nov 24	Option Exercise	1.53	2,340	3,580	26,040	Nov 25 05:00 PM
Virgin Herbert	EVP, Research & CSO	Nov 24	Sale	27.29	2,340	63,848	23,700	Nov 25 05:00 PM
Pang Phillip	Chief Medical Officer	Nov 12	Option Exercise	0.85	20,000	17,100	49,777	Nov 16 05:00 PM
Virgin Herbert	EVP, Research & CSO	Nov 10	Option Exercise	1.53	2,340	3,580	26,040	Nov 12 05:00 PM
Virgin Herbert	EVP, Research & CSO	Nov 10	Sale	26.26	2,340	61,448	23,700	Nov 12 05:00 PM
Pang Phillip	Chief Medical Officer	Nov 04	Option Exercise	1.53	5,000	7,650	34,777	Nov 05 05:00 PM
Parrish Jay	Chief Business Officer	Nov 02	Option Exercise	1.52	6,944	10,520	229,166	Nov 03 05:00 PM
Parrish Jay	Chief Business Officer	Nov 02	Sale	31.27	6,944	217,153	222,222	Nov 03 05:00 PM
Virgin Herbert	EVP, Research & CSO	Oct 27	Option Exercise	1.53	3,805	5,822	27,505	Oct 28 07:43 PM
Virgin Herbert	EVP, Research & CSO	Oct 27	Sale	35.04	3,805	133,335	23,700	Oct 28 07:43 PM
Pang Phillip	Chief Medical Officer	Oct 21	Option Exercise	2.21	12,500	27,667	42,277	Oct 22 06:15 PM
Pang Phillip	Chief Medical Officer	Oct 21	Sale	35.49	12,500	443,608	29,777	Oct 22 06:15 PM
Pang Phillip	Chief Medical Officer	Oct 21	Sale	31.44	5,000	157,209	29,777	Nov 05 05:00 PM
Virgin Herbert	EVP, Research & CSO	Oct 13	Option Exercise	1.53	5,560	8,507	29,260	Oct 14 06:33 PM
Virgin Herbert	EVP, Research & CSO	Oct 13	Sale	43.03	5,560	239,236	23,700	Oct 14 06:33 PM
Pang Phillip	Chief Medical Officer	Oct 07	Option Exercise	1.54	12,500	19,229	42,277	Oct 08 05:00 PM
Pang Phillip	Chief Medical Officer	Oct 07	Sale	41.74	12,500	521,795	29,777	Oct 08 05:00 PM
Parrish Jay	Chief Business Officer	Oct 01	Option Exercise	1.51	6,945	10,522	229,167	Oct 02 05:19 PM
Parrish Jay	Chief Business Officer	Oct 01	Sale	34.75	6,945	241,342	222,222	Oct 02 05:19 PM
Virgin Herbert	EVP, Research & CSO	Sep 29	Option Exercise	1.53	3,510	5,370	27,210	Oct 01 05:00 PM
Virgin Herbert	EVP, Research & CSO	Sep 29	Sale	38.00	3,510	133,380	23,700	Oct 01 05:00 PM
Virgin Herbert	EVP, Research & CSO	Sep 24	Option Exercise	1.53	3,700	5,661	23,700	Sep 28 05:00 PM
Virgin Herbert	EVP, Research & CSO	Sep 22	Option Exercise	1.53	3,805	5,822	23,805	Sep 23 05:00 PM
Virgin Herbert	EVP, Research & CSO	Sep 22	Sale	31.71	3,805	120,638	20,000	Sep 23 05:00 PM
Pang Phillip	Chief Medical Officer	Sep 16	Option Exercise	2.24	12,500	28,001	42,277	Sep 18 05:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience